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Ethanol is neither genotoxic nor mutagenic. Its first metabolite acetaldehyde, however, is a powerful local
carcinogen. Point mutation in ALDH2 gene proves the causal relationship between acetaldehyde and
upper digestive tract cancer in humans. Salivary acetaldehyde concentration and exposure time are the
two major and quantifiable factors regulating the degree of local acetaldehyde exposure in the ideal
target organ, oropharynx. Instant microbial acetaldehyde formation from alcohol represents >70% of
total ethanol associated acetaldehyde exposure in the mouth. In the oropharynx and achlorhydric
stomach acetaldehyde is not metabolized to safe products, instead in the presence of alcohol it accu-
mulates in saliva and gastric juice in mutagenic concentrations. A common denominator in alcohol,
tobacco and food associated upper digestive tract carcinogenesis is acetaldehyde. Epidemiological studies
on upper GI tract cancer are biased, since they miss information on acetaldehyde exposure derived from
alcohol and acetaldehyde present in ‘non-alcoholic’ beverages and food.
© 2017 Published by Elsevier Ltd.The worldwide annual incidence of upper GI tract cancers is
close to 2 million and age standardized rate represents one fourth
of all cancers [1]. The poor prognosis of these cancers underlines
the importance of preventive measures. A key to cancer prevention
is the identification of specific carcinogenic compounds, recogni-
tion of risk groups and early detection of precancerous conditions.
Alcohol and tobacco are major risk factors for oral, pharyngeal and
oesophageal cancer with a synergistic effect on their incidence
[2,3]. They are also independent risk factors for stomach cancer
[4,5]. A common carcinogenic denominator in alcohol, tobacco and
food associated upper GI tract cancer is acetaldehyde, which in the
presence of ethanol accumulates in the saliva and gastric juice.
Acetaldehyde is also the most abundant carcinogen of tobacco
smoke, which dissolves into saliva during smoking [6,7].
The ethanol molecule is neither genotoxic nor mutagenic [8,9].
Acetaldehyde is a group 1 carcinogen to humans, when associated
with the consumption of alcoholic beverages [10]. Group 1 classi-
fication concerns acetaldehyde formed from ethanol by microbialand mucosal oxidation and when present in alcoholic beverages.
Acetaldehyde formation from ethanol starts instantly in saliva
after the sipping of alcohol and continues for as long as ethanol is
present in blood [11,12]. Solid genetic epidemiologic and
biochemical evidence based on a point mutation in the ALDH2 gene
proves the causal relationship between local acetaldehyde expo-
sure and upper GI tract cancer and provides a unique humanmodel
for the quantitative assessment of the carcinogenicity of acetalde-
hyde in man [13].
Exposure of upper GI tract mucosa to carcinogenic acetaldehyde
is cumulative and can be markedly reduced both at population and
individual level. Knowing the key factors regulating local acetal-
dehyde concentration in the upper digestive tract is thus of
essential importance for health care workers, regulatory author-
ities, food and tobacco industry and not least consumers.1. Acetaldehyde
1.1. Main characteristics
Acetaldehyde is a small molecule with orange aroma and low
Table 2
Acetaldehyde concentrations (mg/l) in some widely used alcoholic beverages,
foodstuffs and fruits [16e18]. Mutagenic concentration: 40e100 mM (1.8 e 4 mg/l).
Beverage/foodstuffs n Ranges (mg/l)
Beer (Germany) 364 0e1435
Beer (Italy) 12 3.6e15.1
Wine (Europe) 213 0e211
Wine (Italy) 60 18e477
Grappa (Italy) 13 23e1850
Calvados 27 9e67
Yogurt (Germany)a 23 2.4e17.4
Fruit juicea 4 0.8e19.1
Applesa 8 0.3e2.4
Bananasa 8 1.9e18.3
a If not containing any ethanol, the local exposure time of upper GI tract to
acetaldehyde can be assumed to be considerably lower than that of ethanol con-
taining beverages and food.
Fig. 1. Mutagenic acetaldehyde-DNA adducts in mouthwash samples of healthy hu-
man volunteers after ingestion of alcohol in relation to simulated salivary acetaldehyde
levels. Adapted from Refs. [11,12,19,20]. Alcohol doses 1, 2 and 3 were aimed to reach
0.3, 0.5 and 0.7‰ blood alcohol levels, respectively. In alcohol sipping model used
(Dose 3: diluted vodka at 5 min intervals), salivary acetaldehyde concentration can be
assumed to have been about 150 mM for the first 40 min (max. 260 mM). Within the
following 30 min there is a rapid decrease in salivary acetaldehyde to 20e30 mM for
350 min. Left y-axis: N2-ethylidene-dGuo (fmol/mmol dGuo). Right y-axis: salivary
acetaldehyde (mM).
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easily through the cell membranes. Acetaldehyde is widely present
in our everyday environment. Its characteristics are described in
Table 1.With regards to upper GI tract cancer, most important is the
local in vivo oxidation of ethanol to acetaldehyde in reactions
catalyzed by microbial alcohol dehydrogenase (ADH) enzymes
[11,12]. This results in salivary and gastric juice acetaldehyde con-
centrations, which may exceed markedly its mutagenic level
(40e100 mM, 1.8e4.4 mg/l) and recommended upper limit (5 mg/l)
for cosmetic products [14,15]. Acetaldehyde is also a key metabolite
in the alcoholic fermentation pathway from glucose to ethanol.
Therefore, acetaldehyde is present in mutagenic concentrations in
many alcoholic beverages and foodstuffs produced or preserved by
fermentation (Table 2) [16e18]. Potentially risky acetaldehyde
levels may exist also in some fruits and the substance may be added
to certain foods as a flavouring compound [18].
1.2. Genotoxicity, mutagenicity and carcinogenicity
Acetaldehyde is genotoxic, mutagenic and carcinogenic in vitro
and in vivo [9,10]. It causes DNA-protein crosslinks, DNA strand
breaks, DNA adducts, sister chromatid exchanges, chromosomal
aberrations, and micronuclei in eukaryotic cells. Although many of
these effects have been produced in rather high acetaldehyde
concentrations, there is strong evidence for the generation of spe-
cific mutagenic DNA adducts and induction of micronuclei in
mammalian cells also at acetaldehyde concentrations realistically
achievable from alcoholic beverage consumption [9,10,19].
Oral ingestion of alcohol produces dose dependent mutagenic
acetaldehyde-DNA damage in the oral cavity of humans within
2e4 h (Fig. 1) [19]. In the alcohol sipping model used in that study
salivary acetaldehyde can be assumed to have been about 150 mM
(6.6 mg/l) for the first 40 min (Fig. 1) [11,20]. This profound instant
effect of alcohol on salivary acetaldehyde is most obviously due to
the dose dependent in vitro and in vivo capacity of oral microbes to
produce acetaldehyde in increasing ethanol concentrations
[11,20e22]. Within the following 30 min alcohol is distributed
evenly to the body water including saliva resulting in rapid
decrease in salivary acetaldehyde concentration to mean
20e30 mM for as long as alcohol stays in the blood (Fig. 1) [12].
These findings suggest that the in vivo mutagenic effect of acetal-
dehyde on human oral cells is exponential as indicated also by
earlier in vitro findings on acetaldehyde-DNA adducts [23]. The
formation of mutagenic acetaldehyde-DNA adducts in oral mucosa
caused by local acetaldehyde formation from ethanol has been
confirmed in rhesus monkeys exposed to alcohol over their life-
times [24].Table 1
Acetaldehyde (ethanal).
 CH3 - CHO, orange aroma, boiling point 20.2<SUP>O</SUP>C, soluble in
water and lipids
 Widely present in our everyday environment
 Microbial formation from ethanol
 Key metabolite in alcoholic fermentation
 Most abundant carcinogenic compound of tobacco smoke
 Forms carcinogenic acetaldehyde-DNA adducts
 Genotoxic, mutagenic and carcinogenic even in physiologically relevant
concentrations
 Common denominator for all known risk factors of upper GI tract cancer
 Causal relationship between acetaldehyde and upper GI tract cancer is based
on a single mutation in ALDH2 gene resulting in a profound effect on local
acetaldehyde exposure after alcohol drinkingIn cultured human buccal epithelial cells, mutagenic
acetaldehyde-DNA adducts are formed in vitro in a dose-dependent
manner at acetaldehyde concentrations that are relatively nontoxic
to the cells [25]. Furthermore, aldehyde dehydrogenase 2 (ALDH2)-
deficient alcoholics have significantly higher blood levels of
acetaldehyde-DNA adducts than ALDH2-actives [26,27]. Alcohol
treated ALDH2-deficient mice show increased acetaldehyde-DNA
adduct levels in the liver, stomach and oesophagus [28e30].
Another mutagenic acetaldehyde-DNA adduct (1,N2-prop-
anodeoxyguanosine) increases exponentially in 100e500 mM
acetaldehyde concentrations in the presence of physiological
polyamine concentrations [23]. Polyamine synthesis is tightly
related to cellular proliferation, with the highest levels being found
in rapidly dividing cells, which is characteristic for the regenerating
oral and oesophageal mucosa [31].
According to the International Agency for Research on Cancer
(IARC) acetaldehyde is carcinogenic in experimental animals [10].
Inhaled acetaldehyde produces nasal carcinomas in rats and
laryngeal carcinomas in hamsters [32,33]. Life time administration
of acetaldehyde in drinking-water to rats resulted in increased
Table 3
Human oropharynx as an ideal target organ for the quantitative assessment of the
carcinogenicity of acetaldehyde in alcohol drinking ALDH2-deficients compared to
ALDH2-actives [13].
 Ethanol molecule is not carcinogenic
 Acetaldehyde associated with alcohol consumption is Group 1 carcinogen
 Zero acetaldehyde levels in saliva without the presence of ethanol or tobacco
 Oral mucosa lacks aldehyde dehydrogenase enzymes
 Low or zero capacity of oral microflora to eliminate acetaldehyde
 In ALDH2-deficients additional acetaldehyde is secreted from the salivary
glands
 Adequate data on salivary acetaldehyde in ALDH2-decicients vs. ALDH2-
actives
 Adequate epidemiological data on ALDH2 polymorphisms and oropharyngeal
cancer
 No differences between ALDH2-deficients and ALDH2-actives:
 In the capacity of oral microflora to produce acetaldehyde from ethanol
 In the capacity of oral microflora to eliminate acetaldehyde
 In the mean unstimulated saliva flow rate (0.5 ml/min)
 In the exposure time to salivary acetaldehyde being equal to the rate of
ethanol elimination (7 g/h)
 In confounding factors hampering most epidemiological studies on alcohol
related cancer
- smoking, diet, oral hygiene, human papilloma virus (HPV), use of
different beverages, varying drinking habits, BMI and under reporting
Fig. 2. Oropharyngeal cancer risk (OR) of ALDH2-deficients compared to ALDH2-actives
in relation to the additional exposure of oropharyngeal mucosa to acetaldehyde due to
the deficient ALDH2 enzyme. Adapted from the Tables 1e5 of reference [13].
M. Salaspuro / Best Practice & Research Clinical Gastroenterology 31 (2017) 491e499 493number of pancreatic adenomas, lymphomas, leukaemias, uterine
and mammary gland adenocarcinomas, and head osteosarcomas
[34]. However, no obvious dose-response relationship was
observed in this animal model.
2. ALDH2-deficiency - a unique human cancer model for
acetaldehyde
2.1. Background
A single point mutation in ALDH2 gene results in deficient ac-
tivity of the main acetaldehyde metabolizing low Km mitochon-
drial enzyme (ALDH2). Consequently, ALDH2-deficient subjects are
exposed in the presence of alcohol via saliva 2 to 3 times and via
gastric juice 5 to 6 times higher acetaldehyde concentrations than
those with the active ALDH2-enzyme [35e39]. Parallel to increased
local acetaldehyde exposure, the risk of ALDH2-deficient alcohol
drinkers for oral, pharyngeal, oesophageal and gastric cancer is
many-fold compared to alcohol consuming individuals with the
active ALDH2-enzyme [40e44].
The atypical ALDH2*487Lys allele is probably derived from
ancient Pai-Yuei tribe, which was widely distributed along the
southeast coast of China up to Yunnan Province and the northern
part of Southeast Asia 2000e3000 years ago [45]. Today its carrier
frequency is about 600 million people with Eastern Asian descents
[45,46]. Thus, ALDH2-deficiency is the most prevalent genetic
health risk in the world, passing in frequency that of familial hy-
percholesterolemia (FH). The prevalence of FH is 1:200e250, but
that of ALDH2-deficiency 1:13 [45e47]. Comparable human cancer
model based on a single genemutation is not available for any other
of the IARC group 1 human carcinogens.
2.2. Quantitative assessment of the carcinogenicity of acetaldehyde
in human oropharynx
From one dose of alcohol (10 g ethanol) the human body is able
to produce potentially 217 000 mmoles of acetaldehyde. However,
hepatic aldehyde dehydrogenase enzymes oxidize acetaldehyde
formed from ethanol so effectively that after a moderate dose of
alcohol blood acetaldehyde levels are not detectable in individuals
with normal ALDH2 enzyme, and in ALDH2-deficients they are only
slightly elevated (10 mM) [35e37]. In sharp contrast to the liver,
oral mucosa lacks low Km aldehyde dehydrogenase enzymes and is
thus unable to eliminate acetaldehyde formed microbially from
ethanol [48]. Therefore, alcohol drinking results in mutagenic
salivary acetaldehyde concentrations in both ALDH2-active and
-deficient individuals [11,12,35e37,39]. The capacity of oral mi-
crobes to eliminate acetaldehyde is also low, and in this charac-
teristic, there is no evidence for any differences between ALDH2-
deficients and ALDH2-actives [49].
Human oropharynx provides an ideal target organ for the
quantitative assessment of the carcinogenicity of acetaldehyde in
alcohol drinking ALDH2-deficients compared to ALDH2-actives for
many exceptional reasons (Table 3). Based on five studies with
uniform results salivary acetaldehyde concentration is mean
1.0 mg/l higher in ALDH2-deficients than in ALDH2-actives for as
long as alcohol stays in the human body after its intake [13]. Ac-
cording to alcohol elimination rate (7 g/h) the increased exposure
time to salivary acetaldehyde caused by deficient ALDH2 enzyme is
about 283 min in moderate and 660 min in heavy drinkers [13]. By
multiplying the difference in salivary acetaldehyde concentration
(1 mg/l) between ALDH2-deficients and ALDH2-actives with the
exposure time, the total additional exposure of oropharynx toacetaldehyde is 283 mg/l/283 min in moderate and 660 mg/l/
660min in heavy drinkers, respectively (Fig. 2). Based on onemeta-
analysis and one well done study (total n ¼ 1189 cases and 3239
controls) the ALDH2-deficiency is associated with 1.68e2.61 -fold
oropharyngeal cancer risk in moderate and 3.57e7.28 -fold risk in
heavy drinkers (Fig. 2) [13,40,42]. Oropharyngeal cancer risk of
ALDH2-deficient alcohol drinkers compared to that of ALDH2-
actives correlates thus dose-dependently with the additional
acetaldehyde exposure caused by deficient ALDH2 enzyme (Fig. 2).
Markedly increased risk for oesophageal and gastric cancer in
ALDH2-deficient alcohol drinkers compared to that of ALDH2-
actives indicates that similar dose dependent association between
local acetaldehyde exposure and cancer risk might exist also with
regard to these organs [13,41,43,44]. However, so far there is no
data available on local acetaldehyde concentrations in the
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acetaldehyde concentrations are based only on one study, in which
alcohol was administered intragastrically [38].
In conclusion, a single point mutation in ALDH2 gene has “ran-
domized” millions of alcohol consumers to about two times higher
exposure to carcinogenic acetaldehyde via saliva every time when
they are drinking alcohol and for as long as alcohol stays in their
blood circulation. Since the model is not biased by any significant
confounding factors, ALDH2-deficiency provides a natural and
long-term human model for the quantitative assessment of the
carcinogenicity of acetaldehyde in humans. The model shows that
salivary acetaldehyde concentration and exposure time after
alcohol intake are the twomajor and quantifiable factors regulating
the degree of local acetaldehyde exposure in the oropharynx.
2.3. Practical implications
For any genotoxic and carcinogenic compound, there is an
increased risk for cancer even at low exposure levels. Therefore,
controlling exposure levels to ALARP (As Low as Reasonably Prac-
ticable) should be an overriding principle concerning also acetal-
dehyde [50e52]. However, acetaldehyde still has a ‘generally
recognized as safe’ (GRAS) status validated by the Joint FAO/WHO
Expert Committee on Food Additives (JECFA) in 1998 and the Japan
Flavour and Fragrance Materials Association (JFFMA) in 2015
[53,54]. However, the decision tree for the safety assessment of
flavouring substances applied by JECFA, JFFMA, the Flavour and
Extract Manufactures Association (FEMA) Expert Panel, and the
European Food Safety Authority (EFSA) is based on a critical error
concerning acetaldehyde's metabolism. The WHO model used by
these authorities, predicts that acetaldehyde undergoes complete
metabolism to safe products via acetate [53e55]. This is not,
however, the case with acetaldehyde, which may accumulate in
mutagenic concentrations in saliva and gastric juice in the presence
of even very low ethanol concentrations (10.5 mM, 0.5‰)
[11,12,35e39].
3. Salivary acetaldehyde
Normal human saliva does not contain measurable levels of
acetaldehyde and its unstimulated flow rate ranges from 144 to
2880 ml/day [12,56]. However, acetaldehyde present in saliva in
association with drinking, smoking or eating is distributed evenly
to the water phase of saliva and is transported after each swal-
lowing to the mucosal surfaces of the whole upper digestive tract.
Therefore, all factors having an effect on salivary acetaldehyde
concentration or saliva flow rate is of importance with regard to
the exposure of the upper digestive tract to carcinogenic
acetaldehyde.
3.1. Instant and long-term exposure
Alcohol is distributed to oral mucosal surfaces and saliva
instantly after the ingestion of 40% alcohol solution resulting in up
to 900 mM (4.3%) salivary ethanol concentration at 30 s [11,20].
Microbial acetaldehyde formation from ethanol, instant acetalde-
hyde exposure, starts subsequently within a few seconds after
alcohol intake and continues for 5e10 min after each sip of alcohol
[11,20]. On the other hand, long-term exposure represents acetal-
dehyde formed from ethanol that is diffused to saliva fromblood for
as long as alcohol is present in the human body [12].
One dose of alcohol (10 g ethanol) daily is associated with a
significant relative risk (RR) of 1.29 (20% increase) fororopharyngeal cancer [57]. Assuming that the dose is taken in three
swallows at 5min intervals, oropharyngeal mucosa is exposed to an
average 150 mM (6.6 mg/l) concentration of acetaldehyde for the
first 15 min after alcohol ingestion [11,20]. Thereafter local acetal-
dehyde exposure is rapidly levelling off to about 60 mM (2.6 mg/l)
for the following 10 min and goes further down to about 20 mM
(0.88 mg/l) for the subsequent 55 min [12]. Area under the curve
from zero-time point to 25 min is thus 126 mg/l/25 min repre-
senting up to 72% of the total (174 mg/l/80 min) acetaldehyde
exposure caused by one dose of alcohol.
High levels of acetaldehyde in spirits from Central European
countries and France (Normandy) have been linked to the partic-
ularly high rate of alcohol related upper digestive tract cancers in
these geographical areas [58,59]. This hypothesis is supported by
biochemical findings showing that sipping of alcoholic beverages
containing ‘free’ acetaldehyde from 470 to over 15500 mM results in
a short, 1e2 min' peak (up to 1000 mM) in salivary acetaldehyde
concentration [11,37,60]. Thus, high concentration of ‘free’ acetal-
dehyde present in an alcoholic beverage contributes significantly to
the total instant acetaldehyde exposure of the upper GI tract.
3.2. Major role of oral microflora
Individual characteristics of oral microbiota play a pivotal role in
the regulation of acetaldehyde concentration in the oral cavity and
saliva after alcohol intake [12,21,22,61,62]. This is underlined by a
highly significant correlation (r > 0.9) between in vivo and in vitro
salivary acetaldehyde production in 0.5e1.0‰ ethanol concentra-
tions and by about 50% decrease in salivary acetaldehyde produc-
tion from alcohol after a 3-day use of an antiseptic mouthwash
(chlorhexidine, without ethanol), which associated with a marked
decrease in baseline salivary aerobic and anaerobic bacterial counts
[12].
Some neisseria and viridans group streptococci representing
bacteria in normal oral microflora possess particularly high alcohol
dehydrogenase (ADH) activity and are able to produce in vitro dose
dependent acetaldehyde in increasing ethanol concentrations from
11 mM to 1500 mM (0.5‰ - 7%) [21,22]. The finding indicates
varying and rather high Km values for bacterial ADHs and explains
why in vivo salivary acetaldehyde concentrations are highest (up to
258 mM) immediately after alcohol ingestion resulting in over 1.4%
(300 mM) ethanol concentrations in saliva [11,20]. Also, many
Candida species representing yeasts of normal oral microflora are
characterized by marked capacity to produce acetaldehyde from
ethanol in vitro [61,63e65]. Under low oxygen tension Candida
albicans isolates are able to produce high levels of acetaldehyde
from glucose, too [66].
3.3. Role of mucosa, salivary glands and gene polymorphism
Human oral mucosa has very low ADH activity, 1/10th of that in
the oesophagus and 1/16th of that in the liver [48,67]. Therefore,
the contribution of mucosal ADH to acetaldehyde production from
ethanol in saliva is presumably minimal as suggested also by
studies on 4-methylpyrazole that is an effective inhibitor of the
ADH of somatic cells [36]. Buccal mucosa expresses also ethanol
metabolizing cytochrome CYP2E1 [68]. Its possible role in the
regulation of acetaldehyde level in saliva in the presence of ethanol,
however, is not known.Most importantly, oral mucosa is not able to
eliminate acetaldehyde because of the lack of both cytoplasmic and
mitochondrial low Km ALDH enzymes [48]. This characteristic
apparently plays a decisive role in the accumulation of acetalde-
hyde in saliva after alcohol drinking.
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the presence of ethanol in the systemic blood circulation [20]. This
is in accordance with earlier findings indicating that ethanol is
metabolized to acetaldehyde in the salivary glands [35,36]. How-
ever, due to the deficient activity of salivary gland mitochondrial
ALDH2 enzyme in ALDH2-deficient individuals, the additional
acetaldehyde is secreted from the glands to saliva.
The ADH enzyme encoded by the ADH1C*1 allele metabolizes
ethanol to acetaldehyde 2.5 times faster than that encoded by the
ADH1C*2 allele. In heavy alcohol drinkers, this polymorphism is
associated with increased risk for upper aerodigestive tract cancer,
and in homozygotes, in higher salivary acetaldehyde concentra-
tions following alcohol ingestion than in volunteers heterozygous
for ADH1C or homozygous for ADH1C*2 [69]. Among Japanese al-
coholics the ADH1B*2 allele encoding fast ethanol-metabolizing
ADH enzyme does not have significant effect on salivary acetalde-
hyde levels in the presence of ethanol as compared to those with
the slow-metabolizing ADH1B*1/*1 genotype [39]. However, slow
ADH appears to be associated with the prolonged presence of
ethanol in blood and saliva and thus also with extended exposure
time of the upper digestive tract mucosa to microbially from
ethanol formed acetaldehyde [39].3.4. Role of tobacco smoking and oral hygiene
Acetaldehyde is the most abundant genotoxic carcinogen of
tobacco smoke [6]. It is also present in smoking cessation products
such as electronic cigarettes [70]. As a water-soluble compound,
acetaldehyde dissolves readily in the saliva during smoking and is
by that means distributed to the mucosal surfaces of the upper GI
tract [7]. During smoking, salivary acetaldehyde increases promptly
to mean 261 mM (11.5 mg/l) level and declines after smoking of
about 5 min rapidly back to the basal zero level [7]. The area under
the salivary acetaldehyde curve for 1 cigarette is thus 58mg/l/5 min
and for 4 cigarettes 230 mg/l/20 min/day. In never alcohol drinkers
3e5 cigarettes/day associates with 2.01-fold (OR) for head and neck
cancer [2].
Alcohol, tobacco and poor oral hygiene are established risk
factors for upper digestive tract cancer [2,3,5,42,71]. Smoking and
heavy drinking independently increase in vitro salivary acetalde-
hyde production fromethanol by 60e75% and their combined effect
is about 100% [72]. Poor dental status is associated with infrequent
oral hygiene habits and dental visits, and increases in vitro salivary
acetaldehyde production from ethanol by 100% [73,74]. Chronic
smoking increases also in vivo acetaldehyde production in saliva
from ethanol by about 100% after a moderate dose of alcohol [7].3.5. L-cysteine e salivary acetaldehyde
Exposure of the oropharynx to acetaldehyde derived either from
alcohol or tobacco can be markedly decreased or almost totally
abolished by using special medical devices releasing slowly L-
cysteine [75,76]. L-cysteine is a semi-essential, natural and safe
sulphur-containing amino acid that binds non-enzymatically to
acetaldehyde forming inactive 2-methyltiazolidine-4-
carboxylicacid (MTCA). A buccal tablet containing slow-release L-
cysteine (100mg) decreases the exposure of oropharyngeal mucosa
to acetaldehyde by 60% for 5.3 h after ingestion of a moderate dose
(0.8 g/kg) of alcohol [75]. A lozenge containing 5 or 2.5 mg of L-
cysteine eliminates acetaldehyde from saliva during smoking by
100 and 96%, respectively [76].4. Acetaldehyde and oesophageal cancer
Alcohol and tobacco have a synergistic effect on the risk for
squamous cell oesophageal cancer [3,77]. Other established risk
factors of oesophageal cancer are ALDH2-deficiency in alcohol
drinkers, poor oral health, preserved and fermented food, chronic
oral candidosis and gastric hyposecretion [41,71,78e81]. A common
denominator of all of these cancer hazards is an enhanced exposure
of the oesophageal mucosa to carcinogenic acetaldehyde. However,
alcohol and smoking appear not to be associated with oesophago-
gastric adenocarcinoma as discussed in detail in the other review of
this issue [82].
The regulation of acetaldehyde concentration in the oesophagus
after alcohol intake is much more complicated and far less under-
stood than that in the oropharynx. Alcohol dehydrogenase (ADH)
activity of oesophageal mucosa is 7e12 times higher than in the
tongue and gingiva [48,83]. Furthermore, chronic alcohol con-
sumption induces cytochrome P-450 2E1 (CYP2E1) in the oeso-
phageal mucosa [84]. Both of these enzyme systems are able to
produce acetaldehyde from ethanol, which may contribute signif-
icantly to acetaldehyde delivered to the oesophagus from the
oropharynx with saliva.
In contrast to the oral cavity, oesophageal mucosa has some
aldehyde dehydrogenase enzyme activity, 1/35th of that in the liver
[67,83]. Its role in the local detoxification of acetaldehyde in the
oesophagus is not known. Anyway, ALDH2-deficiency increases
markedly and dose-dependently the risk for oesophageal cancer
among alcohol drinkers, which indicates that oesophageal mucosa
contributes significantly to the exposure of the oesophagus to
carcinogenic acetaldehyde [41].
The normal human oesophagus is colonized with a resident
bacterial flora of its own, which has similarities to that of the oral
mucosa [85]. The most frequent inhabitants of the oesophagus are
streptococci, with an occurrence rate in brush samples and biopsies
of 95e98% [85]. How much these microbes contribute to the
exposure of the oesophageal mucosa to carcinogenic acetaldehyde
derived from ethanol present either in alcoholic beverages or food
is not known.
5. Acetaldehyde and gastric cancer
Gastric cancer is the third leading cause of cancer death in both
sexes worldwide, representing 8.8% of the total cancer mortality
[1,86]. The six-month survival rate is 65% when diagnosed in the
early stages and less than 15% in those diagnosed in the advanced
stage. The five-year survival rate ranges only from 5 to 10%,
underlining the importance of preventive measures [86]. Heli-
cobacter pylori, atrophic gastritis, tobacco smoking, alcohol drink-
ing, ALDH2-deficiency associated with alcohol drinking, pickled
foods, fermented soy food, some fermented dairy products and acid
suppressive drugs are established risk factors for stomach cancer
[4,5,43,44,86e91]. A common denominator behind these gastric
cancer hazards appears again to be carcinogenic acetaldehyde.
5.1. Major role of microbes and gastric mucosa
The normal acidic human stomach is free of microbes. However,
ADH containing and acetaldehyde producing bacteria and yeasts
can survive and even proliferate in the gastric contents of patients
with achlorhydric atrophic gastritis [92,93]. In patients with hypo-
or achlorhydric stomach bacterial overgrowth has been shown to
be associated with the local formation of ethanol (up to
27 mM ¼ 1.3‰) and minor levels (max. 15.7 mM) of acetaldehyde
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acetaldehyde production in patients with hypo- or achlorhydric
stomach secondary either to atrophic gastritis or the use of acid
suppressive drugs is increased to mutagenic levels [38,96e98].
Also, many Helicobacter pylori strains possess ADH activity and are
able to produce acetaldehyde from ethanol under microaerobic
conditions at least in vitro [99].
Gastric mucosal ethanol and acetaldehyde metabolizing en-
zymes are responsible for a significant gastric first-pass metabolism
of alcohol. Stomach mucosa possesses ADH activity representing 1/
3rd of that in the esophagus and 1/12th of that in the liver
[100,101]. In contrast to oropharynx, gastric mucosa contains also
ALDH enzymes with 2.2 times higher activity than in the oesoph-
agus and 1/8th of that in the liver [100,101]. Furthermore, gastric
mucosa expresses some cytochrome P4502E1 activity [102]. How-
ever, the contribution of these various ethanol metabolizing sys-
tems to the regulation of gastric juice acetaldehyde levels in the
presence of alcohol is not so far known.
In individuals with normal acidic stomach and active ALDH2
enzyme intragastric alcohol infusion (0.5 g/kg) causes a slight in-
crease from zero level to mean peak of 10.4 mM in the acetaldehyde
concentration of gastric juice [38]. However, in ALDH2-deficients a
profound elevation to mutagenic acetaldehyde concentrations
(mean peak 47.1 mM) is seen [38]. Highest intragastric acetaldehyde
levels (mean 63.9 mM, range 32.0e96.7 mM) have been demon-
strated in ALDH2-deficient subjects after 7day's treatment with an
acid suppressive drug (rabeprazole 10 mg b.i.d.) and intragastric
alcohol infusion [38]. The alcohol-induced marked increase in
gastric juice acetaldehyde concentrations of hypo- and achlorhy-
dric patients, especially among ALDH2-deficient subjects, provides
strong evidence for the local carcinogenic potential of acetaldehyde
in gastric carcinogenesis.
5.2. L-cysteine e gastric juice acetaldehyde
Local exposure of the gastric mucosa to carcinogenic acetalde-
hyde can be mitigated by slow-release L-cysteine formulations.
After intragastric alcohol installation to patients with atrophic
gastritis 60e70% of carcinogenic acetaldehyde is eliminated to
inactive MTCA after ingestion of two slowly L-cysteine releasing
capsules (2  100 mg) [97,98]. With slow-release L-cysteine peak
acetaldehyde concentrations of gastric juice remained in all pa-
tients under the level of mutagenicity and L-cysteine stayed in the
stomach for up to 3 h. The area under the curve (AUC) for MTCAwas
11-fold higher than that for acetaldehyde, which indicates signifi-
cant gastric first-pass metabolism of ethanol mediated by microbes
and mucosa [98]. With placebo markedly elevated acetaldehyde
levels were found also at low intragastric ethanol concentrations
corresponding to the alcohol levels of many ‘non-alcoholic’ bever-
ages and foodstuffs containing anyway percentage concentrations
of alcohol [38,97,98].
Slow-release L-cysteine eliminated 60e70% of carcinogenic
acetaldehyde also from the gastric juice of both ALDH2-active and
ALDH2-deficent subjects treated with proton pump inhibitor (PPI)
[38]. Nondependent changes in gastric juice and salivary acetal-
dehyde levels caused by ALDH2 deficiency, PPI treatment, and
intragastric L-cysteine indicate that the gastric juice acetaldehyde
concentration is locally regulated by gastric mucosal ADH- and
ALDH2-enzymes and by oral microbes colonizing the achlorhydric
stomach secondary to PPI treatment [38].
Since acetaldehyde formed locally from alcohol in the upper GI
tract is a mutagenic and genotoxic carcinogen in humans, ran-
domized and placebo controlled clinical trials aimed for the pre-
vention of upper GI tract cancers with slowly L-cysteine releasing
formulations will be questionable because of ethical reasons.Therefore, the actual effectiveness of slow-release L-cysteine for-
mulations in cancer prevention remains to be evaluated in pro-
spective intervention studies with established risk groups for
stomach cancer, in which controlling acetaldehyde exposure levels
to ALARP (As Low As Reasonably Practicable) should be an over-
riding principle.
6. Acetaldehyde derived from food e significant
epidemiological bias
Microbial formation of acetaldehyde from ethanol present in
‘non-alcoholic beverages’, fermented foodstuffs or added to the
dish during food preparation forms currently a significant epide-
miological bias in upper GI tract carcinogenesis. Microbial
fermentation has been used for thousands of years to prepare
alcoholic beverages and for the preservation of food. Lactic acid is
the most common end product of food fermentation reactions.
Many microbes are, however, able to produce also ethanol from
sugar under anaerobic conditions. Therefore, beverages and food-
stuffs containing 0.05e2.5% (10.5e525 mM) or even higher con-
centrations of alcohol are widely used in everyday life. Good
examples are home-made mead and beer, vinegar, kefir, mursik
milk, soya sauce, kimchi, pickled food and even some packed bak-
ery products [78,103,104]. Several epidemiological studies have
shown that fermented food products are established risk factors for
upper digestive tract cancer [78,79,88e90].
Excessive use of salt and intragastric formation of potentially
carcinogenic N-nitroso compounds have been suggested to explain
the increased gastric cancer risk associating with the use of these
products. However, salt is neither mutagenic nor carcinogenic, but
an essential additive in food fermentation and preservation. On the
other hand, most recent cohort studies have failed to provide
conclusive evidence with regard to the role N-nitroso compounds
in upper GI tract carcinogenesis [105]. Acetaldehyde associated
with the use of alcoholic beverages is, however, a group 1 carcin-
ogen to humans and there is no evidence that beverages and
foodstuffs containing ethanol up to 2.5% and above and/or muta-
genic concentrations of acetaldehyde is less carcinogenic than
acetaldehyde derived from official alcoholic beverages.
Moreover, alcoholic beverages and ethanol containing sauces
and dressings are frequently used as an essential part of a meal.
Examples are salads, sushi, Marsala, marinating, cooking, flaming
and fondue. In contrast to general belief, alcohol is not evaporated
out of food during cooking. Instead 40e85% of alcohol is retained in
the dish after food preparation resulting in 0.06e4.21%
(13e884 mM) ethanol concentrations in the end product [106].
However, an ethanol level of 10.5e21 mM (0.5e1‰) is more than
enough for the production of mutagenic concentrations of acetal-
dehyde both in vitro and in vivo in the saliva and gastric juice of
individuals with hypo- or achlorhydric stomach
[11,12,20,35e39,95e98]. Depending on eating habits and number
of teeth, these products may expose oropharyngeal and oesopha-
geal mucosa to mutagenic acetaldehyde concentrations for ten to
30 min daily and gastric mucosa for several hours.
In developed countries the decreased incidence of Helicobacter
pylori infection, atrophic gastritis and smoking and the increased
availability of refrigerators and improved oral health have un-
doubtedly had a great decreasing effect both on the incidence of
upper GI tract cancer and as well on the local acetaldehyde expo-
sure in the upper digestive tract. However, the carcinogenic impact
of changing drinking habits and varying concentrations of alcohol
and acetaldehyde in both alcoholic and ‘non-alcoholic’ beverages
and food remains unanswered until this information is made
available for researches, health care workers, regulatory authorities
and consumers.
Practice points
 A point mutation in ALDH2 gene proves the causal rela-
tionship between acetaldehyde and upper GI tract cancer
in humans and provides a novel method for the quanti-
tative assessment of the carcinogenicity of acetaldehyde.
 Local acetaldehyde is a common denominator in alcohol,
tobacco and food associated upper GI tract cancer.
 Microbial acetaldehyde formation starts instantly in saliva
and gastric juice of achlorhydric stomach after alcohol
ingestion and continues for as long as ethanol is present
in the human body.
 Microbial formation of acetaldehyde from ethanol pre-
sent in ‘non-alcoholic’ beverages, fermented food or
added to the dish during food preparation forms a sig-
nificant epidemiologic bias in upper GI tract
carcinogenesis.
 Exposure of upper GI tract mucosa to acetaldehyde is
cumulative and can be markedly reduced both at popu-
lation and individual level.
 Quit from smoking (including electronic cigarettes),
reduce your alcohol consumption, take care of good oral
hygiene, avoid alcoholic beverages containing high levels
of ‘free’ acetaldehyde, avoid ethanol and acetaldehyde
containing ‘non-alcoholic’ beverages and food, and
consider use of slow-release L-cysteine in established risk
groups.
Research Agenda
 Further studies on the role of alcohol, acetaldehyde and
microbes present in ‘non-alcoholic’ beverages and food
in the regulation of local acetaldehyde concentration in
the upper GI tract.
 Further studies on the possible role of food and tobacco
derived acetaldehyde in the formation of mutagenic
acetaldehyde-DNA adducts in the upper digestive tract
mucosa.
 Studies on the effect of saliva flow rate on the exposure of
upper digestive tract mucosa to acetaldehyde.
 Studies on the possible colonization of hypo- or achlor-
hydric stomach by acetaldehyde from ethanol producing
microbes used in the fermentation of alcoholic beverages
and food or as probiotics.
 Intervention studies, in which the exposure of upper GI
tract mucosa to carcinogenic acetaldehyde derived from
ethanol and/or acetaldehyde present in alcoholic and
‘non-alcoholic’ beverages, food and tobacco isminimized
to ALARP (As Low As Reasonably Practicable).
1 *most important.
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